Llerena Claudia, Valbuena Yanely Angélica, Zabaleta Angie Paola, García Angélica Nathalia
Grupo de Micobacterias, Laboratorio Nacional de Referencia, Instituto Nacional de Salud, Bogotá, D.C., Colombia.
Biomedica. 2024 May 30;44(2):182-190. doi: 10.7705/biomedica.7197.
The Mycobacterium chelonae species and the M. avium and M. abscessus complexes are emerging pathogens that cause mycobacteriosis. Treatment depends on the species and subspecies identified. The drugs of choice are macrolides and aminoglycosides. However, due to the resistance identified to these drugs, determining the microbe’s sensitivity profile will allow clinicians to improve the understanding of the prognosis and evolution of these pathologies.
To describe the macrolide and aminoglycoside susceptibility profile of cultures identified by Colombia’s Laboratorio Nacional de Referencia de Mycobacteria from 2018 to 2022, as Mycobacterium avium complex, M. abscessus complex, and M. chelonae. Materials and methods. This descriptive study exposes the susceptibility profile to macrolides and aminoglycosides of cultures identified as M. avium complex, M. abscessus complex, and M. chelonae using the GenoType® NTM-DR method.
This descriptive study exposes the susceptibility profile to macrolides and aminoglycosides of cultures identified as M. avium complex, M. abscessus complex, and M. chelonae using the GenoType® NTM-DR method.
We identified 159 (47.3 %) cultures as M. avium complex, of which 154 (96.9 %) were sensitive to macrolides, and 5 (3.1 %) were resistant; all were sensitive to aminoglycosides. From the 125 (37.2 %) cultures identified as M. abscessus complex, 68 (54.4 %) were sensitive to macrolides, 57 (45.6 %) were resistant to aminoglycosides, and just one (0.8 %) showed resistance to aminoglycosides. The 52 cultures (15.5 %) identified as M. chelonae were sensitive to macrolides and aminoglycosides.
The three studied species of mycobacteria have the least resistance to Amikacin. Subspecies identification and their susceptibility profiles allow the establishment of appropriate treatment schemes, especially against M. abscessus.
龟分枝杆菌、鸟分枝杆菌和脓肿分枝杆菌复合体是引发分枝杆菌病的新兴病原体。治疗方法取决于所鉴定出的菌种和亚种。首选药物是大环内酯类和氨基糖苷类。然而，由于已发现这些药物存在耐药性，确定微生物的药敏谱将有助于临床医生更好地了解这些病症的预后和发展情况。
描述哥伦比亚国家分枝杆菌参考实验室在2018年至2022年期间鉴定的鸟分枝杆菌复合体、脓肿分枝杆菌复合体和龟分枝杆菌培养物对大环内酯类和氨基糖苷类的药敏谱。材料与方法。本描述性研究采用GenoType® NTM-DR方法，揭示了鉴定为鸟分枝杆菌复合体、脓肿分枝杆菌复合体和龟分枝杆菌的培养物对大环内酯类和氨基糖苷类的药敏谱。
本描述性研究采用GenoType® NTM-DR方法，揭示了鉴定为鸟分枝杆菌复合体、脓肿分枝杆菌复合体和龟分枝杆菌的培养物对大环内酯类和氨基糖苷类的药敏谱。
我们鉴定出159株（47.3%）培养物为鸟分枝杆菌复合体，其中154株（96.9%）对大环内酯类敏感，5株（3.1%）耐药；所有菌株对氨基糖苷类均敏感。在鉴定为脓肿分枝杆菌复合体的125株（37.2%）培养物中，68株（54.4%）对大环内酯类敏感，57株（45.6%）对氨基糖苷类耐药，仅有1株（0.8%）对氨基糖苷类耐药。鉴定为龟分枝杆菌的52株培养物（15.5%）对大环内酯类和氨基糖苷类均敏感。
所研究的三种分枝杆菌对阿米卡星的耐药性最低。亚种鉴定及其药敏谱有助于制定合适的治疗方案，尤其是针对脓肿分枝杆菌。
